Resected Melanoma: Subsequent Systemic Therapy After Recurrence on Adjuvant Nivolumab
Source: The Asco Post, August 2024
In an analysis from the phase III CheckMate 238 trial reported in the Journal of Clinical Oncology, Jeffrey Weber, MD, PhD, and colleagues found that progression-free and overall survival were improved with subsequent systemic therapy following late vs early recurrence with adjuvant nivolumab in patients with resected stage IIIB–C or IV melanoma.
Study Details
In CheckMate 238, patients were randomly assigned to receive nivolumab at 3 mg/kg every 2 weeks or ipilimumab at 10 mg/kg every 3 weeks for four doses and then every 12 weeks for either 1 year or until disease recurrence or unacceptable toxicity. Adjuvant nivolumab significantly improved recurrence-free survival vs ipilimumab, with no significant difference in overall survival being observed.
The current analysis investigated outcomes with subsequent systemic therapy following early (? 12 months) and late (> 12 months) disease recurrence on nivolumab. Subsequent systemic therapy included anti–PD-L1/PD-1 monotherapy, anti–CTLA-4 monotherapy, anti–CTLA-4 plus anti–PD-1 therapy, BRAF/MEK inhibitors, and chemotherapy.